Plain-English translation of NCT07233070 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called to see if it can help people recover better after an acute ischemic stroke. Researchers want to understand whether this medication is safe and effective when given to stroke patients within hours of their stroke occurring. About 210 patients will participate, with some receiving the medication and others receiving a placebo (a fake injection) to compare results.
After an ischemic stroke, every hour matters—but current treatment options are limited, especially for patients who arrive too late for some standard therapies. This trial exists to explore whether this new medication might help protect the brain and improve recovery outcomes in patients who have had a recent stroke.
If you qualify, you will receive either the new medication or a placebo as an injection, and neither you nor your doctors will know which one you're getting at first (this is called being 'blinded'). You'll undergo brain imaging and neurological tests to be sure you meet all criteria, and then you'll receive your assigned treatment. The study involves multiple visits over time where doctors will monitor your stroke recovery, check your safety, and measure how well you're doing using standard stroke recovery scales.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Fujian Shengdi Pharmaceutical Co., Ltd.
Enrollment target
~210 participants
Started
October 2025
Primary completion
October 2026
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in June 2026.